JPH05503940A - 新規インスリン組成物 - Google Patents

新規インスリン組成物

Info

Publication number
JPH05503940A
JPH05503940A JP3504590A JP50459091A JPH05503940A JP H05503940 A JPH05503940 A JP H05503940A JP 3504590 A JP3504590 A JP 3504590A JP 50459091 A JP50459091 A JP 50459091A JP H05503940 A JPH05503940 A JP H05503940A
Authority
JP
Japan
Prior art keywords
insulin
ins
general formula
pharmaceutical composition
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3504590A
Other languages
English (en)
Japanese (ja)
Inventor
ハンセン，ヨルゲン　フレデリク
リベル―マドセン，ウルラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JPH05503940A publication Critical patent/JPH05503940A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
  • Medicinal Preparation (AREA)
JP3504590A 1990-02-21 1991-02-21 新規インスリン組成物 Pending JPH05503940A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0455/90 1990-02-21
DK045590A DK45590D0 (2) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
JPH05503940A true JPH05503940A (ja) 1993-06-24

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3504590A Pending JPH05503940A (ja) 1990-02-21 1991-02-21 新規インスリン組成物

Country Status (12)

Country Link
EP (1) EP0516704B1 (2)
JP (1) JPH05503940A (2)
AU (1) AU641991B2 (2)
CA (1) CA2075982A1 (2)
DE (1) DE69100626D1 (2)
DK (1) DK45590D0 (2)
HU (1) HUT63858A (2)
IE (1) IE910579A1 (2)
NZ (1) NZ237176A (2)
PT (1) PT96841A (2)
WO (1) WO1991012817A1 (2)
ZA (1) ZA911279B (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
NZ273285A (en) * 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
ES2472421T3 (es) 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
CA2926701A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
IE910579A1 (en) 1991-08-28
AU7337891A (en) 1991-09-18
DK45590D0 (2) 1990-02-21
PT96841A (pt) 1991-11-29
CA2075982A1 (en) 1991-08-22
HU9202721D0 (en) 1992-12-28
NZ237176A (en) 1991-12-23
EP0516704A1 (en) 1992-12-09
WO1991012817A1 (en) 1991-09-05
DE69100626D1 (de) 1993-12-16
AU641991B2 (en) 1993-10-07
EP0516704B1 (en) 1993-11-10
HUT63858A (en) 1993-10-28
ZA911279B (en) 1991-10-30

Similar Documents

Publication Publication Date Title
EP0516704B1 (en) Novel insulin compositions
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
DE69815877T2 (de) Aggregate von menschlichen insulinderivaten
DE3880346T2 (de) Insulinderivate.
JP4044140B2 (ja) インスリン誘導体類とその使用
EP1274459B1 (en) Sustained release formulations comprising growth hormone
EP0357978B1 (de) Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus
HU227992B1 (en) Interferon conjugates, process for prepairing them, pharmaceutical compositions, containing them and use of them
AU2001259111A1 (en) Sustained release formulations comprising growth hormone
JPH03500286A (ja) 安定なインターフェロン複合体
CH649922A5 (de) Stabilisierte insulinloesungen.
HUT67853A (en) Insulin formulation
DE3789432T2 (de) Hochmolekulare Verbindung, bestehend aus einer Einheit einer zum Asialoglykoproteinakzeptor leitenden Verbindung und aus einer Einheit einer chelatformenden, an dieser chemisch gebundenen, Verbindung, und ihre Verwendung.
EP0193917A2 (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
JPH10511365A (ja) 遅延性ｇｌｐ−１組成物
ZA200600846B (en) Novel insulin derivatives
US5028587A (en) Mixed crystals of insulin and insulin derivatives
JPS59199636A (ja) 放射性診断剤
JP2003504395A (ja) 腎臓に有害な可能性のある分子の腎臓取り込みの阻害
JPS61165331A (ja) 遅延された作用を有する製品およびその製造方法
DE1518057C3 (de) Injizierbares adrenocorticotropes Hormonpräparat mit prolongierter ACTH-Aktivität
JP3042702B2 (ja) 注射用溶液及びその調製方法
EP0458939B1 (de) t-PA pro STABILISIERUNG
EP1620072B1 (en) Zinc-containing sustained-release composition, its preparation, and method for producing the same
EP0397409B1 (en) The stabilization of organic compounds